Physician profile
Kirk Stephens Hinkley
NPI 1366484198
$58,983.98
in general payments reported to CMS, 2019-2025
23 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $459 · 2021: $704 · 2022: $616 · 2023: $775 · 2024: $1,262 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890 · Consulting Fee: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.27 |
| Consulting Fee | $407.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $54,924.62 | 2019-2024 | Vapotherm |
| Novo Nordisk INC | $1,141.90 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $546.79 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Merz North America, INC. | $506.10 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $388.88 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $354.63 | 2021-2025 | Trelegy Ellipta, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.33 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Verona Pharma, INC. | $144.13 | 2025 | Ohtuvayre |
| Amgen INC. | $104.41 | 2023-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $104.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $70.45 | 2021-2025 | Eliquis |
| Indivior INC. | $57.84 | 2023-2025 | Sublocade |
| Organogenesis INC. | $55.72 | 2023 | Puraply |
| Abbvie INC. | $51.41 | 2025 | |
| Abbott Laboratories | $40.09 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $34.90 | 2025 | Brixadi |
| Axsome Therapeutics, INC. | $32.92 | 2025 | Auvelity |
| Astellas Pharma US INC | $28.70 | 2023 | Veozah |
| Si-Bone, INC. | $25.94 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.19 | 2025 | Onpattro |
| Mylan Specialty L.P. | $17.75 | 2019 | |
| Gilead Sciences, INC. | $15.50 | 2020 | |
| Pfizer INC. | $14.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$445,645.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Hinkley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.